# CRVO catalysts: CervoMed Inc. PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/crvo/catalysts

> CervoMed Inc. (CRVO) has 4 upcoming catalysts. The next is the neflamapimod trial start, Q1 2027.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, exact day, quarter only, half-year only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What are the upcoming FDA catalysts for CRVO?

CervoMed Inc. (CRVO) has 4 upcoming catalysts. The next is the neflamapimod trial start, Q1 2027. Press release filed with the SEC (EX-99): "ALS: CervoMed expects dosing of the first patient with neflamapimod in the EXPERTS-ALS trial, which will evaluate neflamapimod for the treatment of ALS, in the first quarter of 2027." [Calendar and source filings](https://sec-api.dev/companies/crvo/catalysts)

Source: Press release filed with the SEC (EX-99), accession 0001437749-26-035885, https://www.sec.gov/Archives/edgar/data/1053691/000143774926035885/ex_1041172.htm (retrieved 2026-11-12). Last confirmed 2026-11-09. Cite: https://sec-api.dev/companies/crvo/catalysts#answer

## Company

| Field | Value |
| --- | --- |
| Name | CervoMed Inc. |
| Ticker | CRVO (Nasdaq) |
| SEC CIK | 1053691 |
| SIC | 2834 |
| SEC filings | https://sec-api.dev/companies/crvo |

## Cash runway

Cash $19.6M as of 2026-09-30; quarterly burn $5.1M; about 11.6 months of runway at that rate (XBRL company facts, accession 0001437749-26-035571).

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| Aug 2023 | [Neflamapimod trial start](https://sec-api.dev/pdufa/neflamapimod) | CRVO | DLB funded primarily | completed | "In the second quarter of 2023, we initiated our ongoing RewinD-LB Trial, a Phase 2b clinical trial of neflamapimod in participants with DLB funded primarily by a $21.3 million grant from the NIA, and, in August 2023, we announced dosing of the first patient in the trial." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1053691/000143774925007829/crvo20241231_10k.htm)) |
| Aug 2024 | [Neflamapimod trial start](https://sec-api.dev/pdufa/neflamapimod) | CRVO |  | completed | "In August 2024, we initiated a Phase 2a study in Strasbourg, France, which will evaluate neflamapimod in up to 20 DLB patients with mild cognitive impairment (MoCA score >= 18 during screening)." ([SEC prospectus (424B)](https://www.sec.gov/Archives/edgar/data/1053691/000143774926021218/crvo20260619c_424b5.htm)) |
| November 8, 2024 | [CervoMed Inc. earnings report](https://sec-api.dev/companies/crvo/catalysts) | CRVO |  | completed | "CervoMed Reports Third Quarter 2024 Financial Results and Provides Corporate Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1053691/000143774924034889/ex_747440.htm)) |
| Dec 2024 | [Neflamapimod topline data readout](https://sec-api.dev/pdufa/neflamapimod) | CRVO | early-stage dementia with Lewy bodies | scheduled | "- Reported last patient, last visit in its RewinD-LB Phase 2b clinical trial evaluating neflamapimod in patients with early-stage dementia with Lewy bodies (DLB) in October 2024; topline data expected in December 2024 -" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1053691/000143774924034889/ex_747440.htm)) |
| Dec 2024 | [CervoMed Inc. topline data readout](https://sec-api.dev/companies/crvo/catalysts) | CRVO |  | scheduled | "We completed enrollment in the RewinD-LB Trial in June 2024, completed the last patient, last visit for the 16-week placebo-controlled phase of the study in October 2024, and expect to report topline results from the placebo-controlled phase of the study in December 2024." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1053691/000143774924034344/crvo20240930_10q.htm)) |
| Dec 2024 | [Neflamapimod trial start](https://sec-api.dev/pdufa/neflamapimod) | CRVO |  | completed | "We believe we are a leader in the industry in developing a treatment for DLB, as we are the only company of which we are aware with an asset that has shown statistically significant improvements compared to placebo in a Phase 2a clinical trial (our AscenD-LB Trial) and has initiated a Phase 2b clinical evaluation (our ongoing RewinD-LB Trial), from which we expect topline results in December 2024." ([SEC prospectus (424B)](https://www.sec.gov/Archives/edgar/data/1053691/000143774926021218/crvo20260619c_424b5.htm)) |
| Dec 2024 | [CervoMed Inc. topline data readout](https://sec-api.dev/companies/crvo/catalysts) | CRVO |  | scheduled | "We believe we are a leader in the industry in developing a treatment for DLB, as we are the only company of which we are aware with an asset that has shown statistically significant improvements compared to placebo in a Phase 2a clinical trial (our AscenD-LB Trial) and that has initiated a Phase 2b clinical evaluation (our ongoing RewinD-LB Trial), from which we expect topline results in December 2024." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1053691/000143774924034344/crvo20240930_10q.htm)) |
| Q1 2025 | [Neflamapimod topline data readout](https://sec-api.dev/pdufa/neflamapimod) | CRVO |  | scheduled | ""Our next data readout, from the first 16 weeks of the OLE phase of the trial, will be available in the first quarter of 2025 and will include data on a range of global, cognitive and motor efficacy endpoints, as well as pharmacokinetic data, obtained from a sizeable subgroup of participants who are receiving capsules of neflamapimod manufactured more recently than the capsules utilized during the double-blind phase of the study." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1053691/000143774925002329/ex_772642.htm)) |
| March 17, 2025 | [CervoMed Inc. earnings report](https://sec-api.dev/companies/crvo/catalysts) | CRVO |  | completed | "CervoMed Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1053691/000143774925008249/ex_791644.htm)) |
| Q2 2025 | [Neflamapimod trial start](https://sec-api.dev/pdufa/neflamapimod) | CRVO | frontotemporal dementia | scheduled | "In the second quarter of 2025, CervoMed plans to initiate the Phase 2 Restore Trial to evaluate neflamapimod in patients recovering from ischemic stroke." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1053691/000143774925008249/ex_791644.htm)) |
| May 12, 2025 | [CervoMed Inc. earnings report](https://sec-api.dev/companies/crvo/catalysts) | CRVO |  | completed | "CervoMed Reports First Quarter 2025 Financial Results and Provides Corporate Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1053691/000143774925016131/ex_816257.htm)) |
| August 11, 2025 | [CervoMed Inc. earnings report](https://sec-api.dev/companies/crvo/catalysts) | CRVO |  | completed | "CervoMed Reports Second Quarter 2025 Financial Results and Provides Corporate Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1053691/000143774925025814/ex_850337.htm)) |
| November 10, 2025 | [CervoMed Inc. earnings report](https://sec-api.dev/companies/crvo/catalysts) | CRVO |  | completed | "CervoMed Reports Third Quarter 2025 Financial Results and Provides Corporate Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1053691/000143774925034095/ex_885764.htm)) |
| March 17, 2026 | [CervoMed Inc. earnings report](https://sec-api.dev/companies/crvo/catalysts) | CRVO |  | completed | "CervoMed Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1053691/000143774926008611/ex_933983.htm)) |
| May 18, 2026 | [CervoMed Inc. earnings report](https://sec-api.dev/companies/crvo/catalysts) | CRVO |  | completed | "CervoMed Reports First Quarter 2026 Financial Results and Provides Corporate Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1053691/000143774926017637/ex_964814.htm)) |
| 2H 2026 | [Neflamapimod topline data readout](https://sec-api.dev/pdufa/neflamapimod) | CRVO |  | scheduled | "Multiple potential catalysts anticipated in the second half of 2026, including initiation of the planned Phase 3 trial, topline data from Phase 2a ischemic stroke recovery trial, initial topline data from Phase 2a primary progressive aphasia trial, and initiation of EXPERTS-ALS trial in Amyotrophic Lateral Sclerosis" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1053691/000143774926008611/ex_933983.htm)) |
| 2H 2026 | [Neflamapimod interim data readout](https://sec-api.dev/pdufa/neflamapimod) | CRVO |  | scheduled | "The Company also expects to report initial biomarker data from the trial in mid-2026 and initial topline 24-week biomarker and clinical and data from the trial in the second half of 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1053691/000143774926017637/ex_964814.htm)) |
| August 10, 2026 | [CervoMed Inc. earnings report](https://sec-api.dev/companies/crvo/catalysts) | CRVO |  | completed | "CervoMed Reports Second Quarter 2026 Financial Results and Provides Corporate Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1053691/000143774926026771/ex_1002031.htm)) |
| November 9, 2026 | [CervoMed Inc. earnings report](https://sec-api.dev/companies/crvo/catalysts) | CRVO |  | completed | "CervoMed Reports Third Quarter 2026 Financial Results and Provides Corporate Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1053691/000143774926035885/ex_1041172.htm)) |
| Q1 2027 | [Neflamapimod trial start](https://sec-api.dev/pdufa/neflamapimod) | CRVO | DLB, enriched for those without AD co-pathology | scheduled | "ALS: CervoMed expects dosing of the first patient with neflamapimod in the EXPERTS-ALS trial, which will evaluate neflamapimod for the treatment of ALS, in the first quarter of 2027." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1053691/000143774926035885/ex_1041172.htm)) |
| Q1 2027 | [Neflamapimod interim data readout](https://sec-api.dev/pdufa/neflamapimod) | CRVO |  | scheduled | "The Company also expects to report initial topline clinical data, as well as additional biomarker data, in the first quarter of 2027." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1053691/000143774926026771/ex_1002031.htm)) |
| Q1 2027 | [Neflamapimod topline data readout](https://sec-api.dev/pdufa/neflamapimod) | CRVO |  | scheduled | "We look forward to presenting 24-week biomarker data at the Clinical Trials on Alzheimer's Disease conference in November, followed by topline clinical data in the first quarter of 2027."" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1053691/000143774926032502/ex_1024863.htm)) |
| Q2 2027 | [Neflamapimod topline data readout](https://sec-api.dev/pdufa/neflamapimod) | CRVO |  | scheduled | "The Company expects to report initial 24-week clinical data, as well as additional biomarker data, at the Alzheimer's & Parkinson's Diseases Conference in March 2027, and full topline data from the trial in the second quarter of 2027." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1053691/000143774926035885/ex_1041172.htm)) |

## Drugs

- [Neflamapimod](https://sec-api.dev/pdufa/neflamapimod): dlb, enriched for those without ad co-pathology, dementia with lewy bodies in second half of 2026, subject to financing, frontotemporal dementia, dlb funded primarily, early-stage dementia with lewy bodies, early-stage dlb in october 2024 and remain

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/crvo/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "CRVO catalysts: CervoMed Inc. PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/crvo/catalysts

```bibtex
@misc{secapidev_companies_crvo_catalysts_20261116,
  title        = {CRVO catalysts: CervoMed Inc. PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/crvo/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_crvo_catalysts_20261116","title":"CRVO catalysts: CervoMed Inc. PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/crvo/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
